Serum osteopontin is a predictor of prognosis for HBV‑associated acute‑on‑chronic liver failure

  • Authors:
    • Longgen Liu
    • Jianchun Lu
    • Chunyan Ye
    • Lin Lin
    • Shuqin Zheng
    • Hongyu Zhang
    • Qing Lan
    • Yuan Xue
  • View Affiliations

  • Published online on: December 13, 2017     https://doi.org/10.3892/br.2017.1027
  • Pages:166-171
Metrics: HTML 0 views | PDF 0 views     Cited By: 0 citations

Abstract

Acute‑on‑chronic liver failure (ACLF) is a syndrome with a high rate of short‑term mortality, and clinically it is important to identify patients at high risk of mortality. The present study evaluated the value of osteopontin (OPN) in the prediction of 90‑day mortality in patients with ACLF. A total of 54 patients with HBV‑associated ACLF were enrolled, and serum OPN levels were determined in a prospective, observational study design. Survival analysis was performed using Kaplan‑Meier curves, and multivariate Cox proportional hazards regression was used to analyze independent risk factors of mortality. Serum OPN was significantly higher in HBV‑ACLF patients compared with patients with chronic hepatitis B and healthy controls (both P<0.01), and furthermore, was higher in those patients who succumbed to HBV‑ACLF compared with surviving patients (P<0.05). OPN level positively correlated with total bilirubin (r=0.554, P<0.001), Model for End‑Stage Liver Disease (MELD) score (r=0.234, P=0.038), MELD‑Na score (r=0.379, P=0.005) and monocyte count (r=0.282, P=0.039), and OPN was an independent risk factor for 90‑day mortality in ACLF (P=0.021, odds ratio=1.104, 95% confidence interval: 1.003‑1.116). Furthermore, ACLF patients were stratified into three groups according to serum OPN levels (low mortality risk: <6,135 ng/ml; intermediate risk: 6,135‑9,043 ng/ml; and high risk: >9,043 ng/ml), for which the 90‑day mortality rates were 27.78 (5/18), 52.94 (9/17) and 73.68% (14/19), respectively, and those in the high risk had a poorer prognosis compared with the low risk group (P=0.009). In conclusion, serum OPN may be an independent risk factor associated with HBV‑ACLF prognosis.

Related Articles

Journal Cover

February 2018
Volume 8 Issue 2

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, L., Lu, J., Ye, C., Lin, L., Zheng, S., Zhang, H. ... Xue, Y. (2018). Serum osteopontin is a predictor of prognosis for HBV‑associated acute‑on‑chronic liver failure. Biomedical Reports, 8, 166-171. https://doi.org/10.3892/br.2017.1027
MLA
Liu, L., Lu, J., Ye, C., Lin, L., Zheng, S., Zhang, H., Lan, Q., Xue, Y."Serum osteopontin is a predictor of prognosis for HBV‑associated acute‑on‑chronic liver failure". Biomedical Reports 8.2 (2018): 166-171.
Chicago
Liu, L., Lu, J., Ye, C., Lin, L., Zheng, S., Zhang, H., Lan, Q., Xue, Y."Serum osteopontin is a predictor of prognosis for HBV‑associated acute‑on‑chronic liver failure". Biomedical Reports 8, no. 2 (2018): 166-171. https://doi.org/10.3892/br.2017.1027